News
Cadila Pharmaceuticals and Altus Formulation Announce Successful Clinical Studies with TramaFlex Breakable Extended-Release Tablets
Successful Validation of Novel AmyloFlextm Modified Release Technology Platform: New Safer to Use Value Added Tablets AHMEDABAD, INDIA and LAVAL, QC / ACCESSWIRE / January 27, 2021 / Cadila Pharmaceuticals Limited ("Cadila") and Altus Formulation Inc. ("Altus") today...
Head of Business & Corporate Development
Altus Formulation is an R&D focused pharmaceutical development company with a suite of proprietary drug delivery technologies and a rapidly growing portfolio of co-development and licensing agreements with a range of global partners. Altus is seeking a Head of...
Recipharm Signs Licensing Agreement with Altus Formulation
MONTREAL, QC / ACCESSWIRE / March 5, 2018 / Recipharm, the contract development and manufacturing organisation (CDMO), has signed a licensing agreement with Altus Formulation Inc., a Canadian drug development company, to allow its customers to access new drug delivery...
FLEXITAB Safer Use Extended Release Tablets
Altus is pleased to present FLEXITABTM, an innovative and commercially validated technology platform providing novel, value added life-cycle management opportunities through Safer UseTM breakable, extended release (ER) tablets. Conventional ER tablets may ‘dose dump’...
ALTUS ANNOUNCES ALLOWANCE OF NEW FLEXITABTM PATENTS IN EUROPE
Altus Formulation Inc. a Quebec based drug development company, leveraging its patented delivery technologies to develop novel Safer to UseTM formulations for its partners and their patients is pleased to announce the allowance of its first FLEXITABTM patent in Europe...
PERNIX PRESENTS DATA ON NOVEL EXTENDED RELEASE FORMULATION OF HYDROCODONE BITARTRATE AT PAINWEEK
Next-Generation Tablet Formulation Resists Physical Manipulation and Extraction of Hydrocodone In Vitro Data Supports Further Human Abuse Liability Studies LAS VEGAS, NV – September 9, 2015 (GLOBAL NEWSWIRE) – Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a...
PERNIX RELEASES POSITIVE IN VITRO ABUSE DETERRENT DATA FOR THIRD GENERATION EXTENDED RELEASE HYDROCODONE ZX007
MORRISTOWN, N.J., July 27, 2015 (GLOBAL NEWSWIRE) – Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced positive results from Category 1 (in vitro) abuse deterrence studies with ZX007, utilizing Altus Formulation’s...
Canadian Intellitab Patents
Montreal, Quebec, Canada Altus Formulation Inc. a Quebec – based drug formulation and development company, leveraging it’s patented drug delivery technologies to develop Safer to UseTM formulations for its partners and their patients today announced the issuance of...
ZX007, Altus’ INTELLITAB formulation of hydrocodone completes successful pharmacokinetic study
MORRISTOWN, N.J., May 05, 2015 (BUSINESS WIRE) -- Pernix Therapeutics Holdings, Inc. PTX, +0.94% a specialty pharmaceutical company, today announced the successful completion of a human pharmacokinetic equivalence study with ZX007, an innovative abuse deterrent tablet...
Altus Formulation Inc. Launches New European Business Initiative for INTELLITAB
Altus Formulation Inc. Montreal Monday February 2nd. 09:00 Altus Formulation Inc. is a Canadian Drug Formulation and Development Company, leveraging our patented drug delivery technologies to develop Safer to UseTM formulations for our partners and their patients....